Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists

Hickman, Lisa C.; Valentine, Lindsey N.; Falcone, Tommaso

doi:10.1016/j.ajog.2016.06.053

Cited by 25 publications

(15 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gonadotropin-releasing hormone agonist administration or egg/sperm collection may be employed to preserve fertility following cyclophosphamide use. 110 …”

Section: Second-line Immunotherapymentioning

confidence: 99%

Treatment strategies for autoimmune encephalitis

Shin

Park

Jung

et al. 2017

Ther Adv Neurol Disord

182

192

View full text Add to dashboard Cite

Autoimmune encephalitis is one of the most rapidly growing research topics in neurology. Along with discoveries of novel antibodies associated with the disease, clinical experience and outcomes with diverse immunotherapeutic agents in the treatment of autoimmune encephalitis are accumulating. Retrospective observations indicate that early aggressive treatment is associated with better functional outcomes and fewer relapses. Immune response to first-line immunotherapeutic agents (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunoadsorption) is fair, but approximately half or more of patients are administered second-line immunotherapy (rituximab and cyclophosphamide). A small but significant proportion of patients are refractory to all first- and second-line therapies and require further treatment. Although several investigations have shown promising alternatives, the low absolute number of patients involved necessitates more evidence to establish further treatment strategies. In this review, the agents used for first- and second-line immunotherapy are discussed and recent attempts at finding new treatment options are introduced.

show abstract

“…Gonadotropin-releasing hormone agonist administration or egg/sperm collection may be employed to preserve fertility following cyclophosphamide use. 110 …”

Section: Second-line Immunotherapymentioning

confidence: 99%

Treatment strategies for autoimmune encephalitis

Shin

Park

Jung

et al. 2017

Ther Adv Neurol Disord

182

192

View full text Add to dashboard Cite

show abstract

“…Gonadotropin-releasing hormone agonists : The use of gonadotropin-releasing hormone agonists (GnRHa) is an investigational strategy, based on the use of GnRHa to suppress ovarian function during CHT. Theoretically, the use of GnRHa reduces the gonadotropins level, placing the ovaries in an artificial prepubertal state [ 26 ]. Moreover, studies of ovarian tissue have led to the hypothesis that these compounds could be able to reduce the organ damage and the local ischaemia caused by chemotherapeutic agents.…”

Section: Fertility Preservation Strategiesmentioning

confidence: 99%

Fertility preservation in gynaecologic cancers

Felice¹,

Marchetti²,

Pinto³

et al. 2018

ecancer

View full text Add to dashboard Cite

Due to substantial improvement in the diagnosis and treatment of gynaecologic cancers, a better understanding of patient care needs to be revised. We reviewed the literature related to fertility preservation strategies in gynaecological cancer and discussed current general management approaches. New technical modalities and patients’ own desire for motherhood should be integral and paramount in the clinical evaluation to significantly contribute to preserving fertility in those women diagnosed with gynaecologic cancers during the reproductive years.

show abstract

“…4. A GnRH-agonistáknak valószínűleg védőszerepük van a petefészekcsíra-, őssejtvonalra [46]. Nagy randomizált tanulmányok tervezésével meghatározható lenne ezeknek a gyógyszereknek a biztos haté-konysága.…”

Section: Adjuváns Gyógyszeres Kezelés -Gnrh-agonistákunclassified

Onkofertilitás és kezelési lehetőségei. Irodalmi áttekintés

Sápy

Póka

2017

Orvosi Hetilap

View full text Add to dashboard Cite

A rosszindulatú daganatos betegségek műtétes, sugár-, kemo-és biológiai terápiás kezelése káros hatással lehet a fiatal betegek későbbi fertilis képességeire. A javuló gyógyulási esélyek mellett egyre nagyobb hangsúlyt kap a betegek hosszú távú életminősége, így a túlélésen túl jövőbeli fertilitásuk megőrzése is célként fogalmazódik meg. Az onkológiai és fertilitásmegtartási törekvéseket az onkofertilitás kifejezés foglalja össze. Ez alatt nemcsak speciális nőgyó-gyászati műtéti eljárásokat értünk, hanem olyan beavatkozásokat is, amelyek az ivarsejtek, a nemi szervek vagy az embrió konzerválását célozzák. Az onkofertilitás mint kifejezés az Amerikai Egyesült Államokban született, de napjainkban már az egész világon interdiszciplináris tudományterületként egyre nagyobb teret hódítva válik egyre több szakember speciális érdeklődési területévé. A klasszikus onkológiai és nőgyógyászati szubspecialitások mellett az onkofertilitás ismeretanyaga is olyan szintre emelkedik, amelynek naprakész tudása az egyes modalitások szakembereitől már nem várható el. Az onkológus, a sugárterapeuta, a sebész és a meddőségi specialista eseti együttműködését az onkofertilitásra specializálódott szakemberek útmutatása teheti igazán hatékonnyá. Orv Hetil. 2017; 158(18): 683-691. Kulcsszavak: onkofertilitás, fertilitásmegtartás, cryopraeservatio, oophoropexia, trachelectomia Oncofertility and therapeutic modalities Survey of literatureSurgical and radiological treatment as well as chemotherapy and biological therapy may have harmful effects on young patients' future fertility. Increasingly greater emphasis has been put on ensuring these patients' long-term quality of life, therefore, in addition to survival, preserving their prospective fertility is also among our aims. The term 'oncofertility' has been compounded from two expressions, 'oncology' and attempts to 'fertility preservation'. In gynecology, fertility preservation involves not only special surgical procedures but also interventions intended to preserve gametes, reproductive organs and embryos. Although the term 'oncofertility' was created in the United States of America, it has become an interdisciplinary field of science worldwide. By gaining grounds steadily, it has attracted special attention among experts. In addition to the subdivisions of classical oncology and gynecology, knowledge of oncofertility is broadening so rapidly that one cannot expect experts to be 100% up-to-date in one or another modality. It is special guidance by consultants in oncofertility that can make occasional co-operation among oncologists, radiotherapists, surgeons and infertility specialists really effective. ÖSSZEFOGLALÓ KÖZLEMÉNYRövidítések AFC = antral follicle count; AMH = anti-Müllerian-hormon; ART = abdominalis radikális trachelectomia; DNS = dezoxiribonukleinsav; E 2 = ösztradiol; FSH = folliculusstimuláló hormon; G = grade; GnRH = gonadotrop releasing hormon; Gy = gray; ICSI = intracitoplazmatikus spermium injekció; IVF = in vitro fertilisatio; LEEP = loop electrosurgical excision procedu...

show abstract

Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists

Cited by 25 publications

References 49 publications

Treatment strategies for autoimmune encephalitis

Treatment strategies for autoimmune encephalitis

Fertility preservation in gynaecologic cancers

Onkofertilitás és kezelési lehetőségei. Irodalmi áttekintés

Contact Info

Product

Resources

About